Risk of cardiovascular toxicity with combination of immune-checkpoint inhibitors and angiogenesis inhibitors: a meta-analysis

• DOI: 10.3389/fcvm.2024.1309100
• Publication Date: 2024-02-02T04:38:07Z
• Authors: Alessandro Inno; Antonello Veccia; Giorgio Madonia; Alvise Berti; Roberto Bortolotti; Lorena Incorvaia; Antonio Russo; Orazio Caffo; Stefania Gori
• Keywords: Stroke

Introduction Combinations of immune checkpoint inhibitors (ICIs) and angiogenesis (AIs) have been investigated for the treatment several tumor types. Both ICIs AIs may lead to cardiovascular adverse events, their combination potentially increase risk toxicity. In present meta-analysis, we aim assess toxicity plus vs. alone. Secondary objectives are non-cardiovascular events efficacy. Methods Systematic review was performed according PRISMA statement. Phase II III randomized clinical trials were identified by searching MEDLINE/PubMed, Cochrane Library ASCO Meeting abstracts, from inception June 2022. The pooled risks overall response rate (ORR), 1-year progression-free survival (PFS), (AEs), immune-related AEs, (irAEs), hypertension, vascular defined as stroke, myocardial infarction pulmonary embolisms, calculated. Results terms toxicity, found higher severe hypertension among patients treated with compared those receiving (OR 1.24, 95% CI: 1.01–1.53), but no significant difference any-grade events. There also in whereas incidence irAEs increased arm, expected. efficacy, achieved better ORR 2.25, 1.70–2.97) PFS (HR 0.49, 0.39–0.63) Conclusion addition significantly high-grade not that acute